论文部分内容阅读
目的比较东菱克栓酶及其联合蚓激酶两组方法对急性脑梗死近远期疗效影响。方法对120位患者随机分为东菱克栓酶治疗组和联合治疗组,测定血浆纤维蛋白浓度,试验组以东菱克栓酶较大剂量静点联合蚓激酶口服,对照组采用东菱克栓酶较大剂量治疗方案,评价治疗前和治疗后24小时,1周,2周,4周的神经功能缺损评分。结果东菱克栓酶的治疗停后的2周纤维蛋白原上升至用药前水平。结论两组对急性脑梗死有明显的疗效。试验组明显降低急性脑梗死远期复发率,可在预防和治疗缺血性脑血管疾病中推广应用。
Objective To compare the short-term and long-term curative effects of two methods of combining Bollzyme and Lumbrokinase on acute cerebral infarction. Methods One hundred and twenty patients were randomly divided into two groups: the untreated group and the combined treatment group. The plasma fibrin concentration was measured. In the test group, the bolloclone combined with bollodrine and lumbrokinase were administered orally. In the control group, A larger dose of thrombolytic therapy regimen was used to evaluate neurological deficit scores before and 24 hours, 1 week, 2 weeks and 4 weeks after treatment. Results of the treatment of rhubarb thrombin 2 weeks after the withdrawal of fibrinogen rose to the level before treatment. Conclusion Both groups have obvious curative effect on acute cerebral infarction. The experimental group significantly reduce the long-term recurrence rate of acute cerebral infarction, which can be used in the prevention and treatment of ischemic cerebrovascular disease.